CJC-1295 + Ipamorelin: why the blend is studied
The CJC-1295 ipamorelin blend combines CJC-1295 without DAC (also called modified GRF 1-29), a short-acting GHRH analog, with ipamorelin, a ghrelin-receptor agonist. The pairing has a receptor-level rationale because the components signal through different pathways, but the primary studies cited here evaluated the compounds separately—not this commercial combination. Supplied as a single ≥98% purity, HPLC-tested lyophilised vial for laboratory research use only.
Specifications
| Components | CJC-1295 (no DAC) + ipamorelin |
|---|---|
| Receptor targets | GHRH receptor + GHS-R1a (ghrelin receptor) |
| Vial size | 10mg total (5mg + 5mg) |
| Evidence basis | Component studies; no blend-specific study cited |
| Purity | ≥98% (HPLC) |
| Form | Lyophilised powder, single vial |
Two receptor pathways, one research question
CJC-1295 without DAC (modified GRF 1-29) is a GHRH analog intended to signal through the pituitary GHRH receptor. Ipamorelin belongs to a different class: it activates the growth-hormone secretagogue receptor GHS-R1a, commonly called the ghrelin receptor.
These receptors participate in distinct inputs to growth-hormone release. That gives the pairing a mechanistic rationale for laboratory designs examining both pathways, but a plausible mechanism is not proof of additive or synergistic effects. The primary papers cited on this page tested the components separately.
What the ipamorelin study established
Raun and colleagues characterised ipamorelin in rat and swine models, comparing growth-hormone release with effects on ACTH and cortisol. The paper described ipamorelin as a selective growth-hormone secretagogue in those animal experiments (Raun et al., 1998).
That foundational result is preclinical. It does not establish the same endocrine selectivity in humans, and it did not evaluate ipamorelin in combination with CJC-1295. Claims about the blend therefore should not be presented as outcomes demonstrated by the Raun study.
What the human CJC-1295 studies established
Teichman and colleagues conducted two randomised, placebo-controlled studies of long-acting CJC-1295 in healthy adults. The molecule studied included the Drug Affinity Complex (DAC), which extends exposure through covalent binding to albumin. Reported mean terminal half-life was approximately 5.8 to 8.1 days; after a single administration, mean GH concentrations increased for at least six days and mean IGF-1 concentrations for nine to eleven days (Teichman et al., 2006).
A related analysis found that growth-hormone secretion remained pulsatile during the prolonged stimulation produced by CJC-1295 with DAC (Ionescu & Frohman, 2006). These findings describe the long-acting DAC molecule, not the no-DAC component in this blend.
CJC-1295 with DAC is not the no-DAC blend component
CJC-1295 with DAC and CJC-1295 without DAC are not interchangeable labels. The DAC modification creates the albumin-binding, long-exposure behavior measured in the cited human studies. The blend sold on this site contains the no-DAC form, commonly called modified GRF 1-29.
No equivalent human pharmacokinetic dataset for the no-DAC component is cited here. It would therefore be inaccurate to transfer the 5.8-to-8.1-day half-life or the multi-day GH and IGF-1 findings from the DAC studies to this blend.
What has not been established for the blend
The primary literature reviewed for this guide does not include a controlled study in which CJC-1295 and ipamorelin were administered as this combined 1:1 formulation. There is no blend-specific outcome, pharmacokinetic profile or optimized component ratio established by the three cited papers.
The 10mg vial contains 5mg of each component as a commercial laboratory formulation. That ratio should not be confused with a published dose-ranging result or a recommendation for use. Research designs should treat identity, ratio, model, controls and analytical endpoints as separate variables.
- Ipamorelin evidence cited here: animal pharmacology, single compound.
- CJC-1295 evidence cited here: healthy-adult studies of the DAC form, single compound.
- Combination evidence cited here: none; receptor biology supplies a hypothesis, not a demonstrated blend effect.
Interpreting the evidence in laboratory research
Species, molecular form and exposure duration materially affect interpretation. Animal ipamorelin findings cannot be assumed to reproduce in humans, while long-acting CJC-1295-DAC findings cannot be assumed to describe modified GRF 1-29. A study that changes more than one of these variables cannot attribute an observation to either component without suitable controls.
For analytical work, researchers can document the exact component identity, lot, measured purity, reconstitution conditions, storage history and time after preparation. Separate-component controls may help distinguish a combination observation from the behavior of either compound alone.
Handling in the lab
Store unopened lyophilised material cold, dry and protected from light. Record the lot and storage history, minimize repeated temperature changes, and follow the laboratory's validated procedure for the intended assay.
If a protocol requires solution preparation, use an appropriate sterile diluent and aseptic technique, avoid vigorous agitation, label the final concentration and preparation time, and keep prepared solutions refrigerated. The reconstitution and storage guides provide general laboratory handling context, not dosing guidance.
Frequently asked questions
What is the CJC-1295 ipamorelin blend?
A single research vial combining CJC-1295 without DAC (a GHRH analog) and ipamorelin (a ghrelin-receptor agonist) — two compounds that signal through different receptor pathways associated with growth-hormone release.
Which form of CJC-1295 is in the blend?
CJC-1295 without DAC, commonly called modified GRF 1-29. It is distinct from the long-acting CJC-1295-DAC molecule evaluated in the cited human studies.
Is there a published study of CJC-1295 and ipamorelin together?
The primary literature cited in this guide does not include a controlled study of this combined formulation. The cited CJC-1295 and ipamorelin papers evaluated the compounds separately.
Why pair a GHRH analog with a ghrelin-receptor agonist?
The components signal through different receptors: the GHRH receptor and GHS-R1a. That creates a receptor-level research hypothesis, but it does not by itself prove additive or synergistic effects.
What did the human CJC-1295 studies test?
They tested long-acting CJC-1295 with DAC in healthy adults and measured pharmacokinetics, GH, IGF-1 and safety variables. They did not test the no-DAC form used in this blend or a combination with ipamorelin.
Can the CJC-1295-DAC half-life be applied to this blend?
No. The reported 5.8-to-8.1-day terminal half-life belongs to CJC-1295 with DAC. The blend contains CJC-1295 without DAC, so transferring that exposure profile would be scientifically inaccurate.
What evidence supports ipamorelin selectivity?
Raun et al. characterised ipamorelin as a selective growth-hormone secretagogue in rat and swine experiments. That is preclinical evidence and does not establish identical endocrine effects in humans.
Is the 5mg plus 5mg blend ratio based on a clinical trial?
No blend-specific dose-ranging study is cited for the 1:1 commercial formulation. The vial ratio is a product specification, not a published optimized ratio or a use recommendation.
Are CJC-1295 or ipamorelin FDA-approved medicines?
No. Neither the CJC-1295 forms discussed here nor ipamorelin is an FDA-approved medicine. PeptidesDirect supplies these materials only for laboratory research.
Where can I buy the CJC-1295 ipamorelin blend for research?
PeptidesDirect sells the blend in 10mg vials for laboratory research only. Orders placed before 1:00 PM Central on business days ship the same day. See our research peptides guide research peptides guide for how to compare suppliers and read test documents.
Product pages: CJC-1295 / Ipamorelin blend 10mg · Ipamorelin · CJC-1295 with DAC
How should the blend be stored?
Keep lyophilised vials cold, dry and protected from light. Record storage history and refrigerate prepared solutions according to the laboratory's validated protocol. See the linked storage and reconstitution guides for general handling context.
Is this product for human use?
No. PeptidesDirect sells this compound for laboratory research only. It is not a drug, food or cosmetic and is not for human or veterinary use. This page summarises published research and is not dosing or medical guidance.
Shop the compounds covered in these FAQs: CJC-1295 / Ipamorelin blend 10mg · Ipamorelin · CJC-1295 with DAC
References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006. PubMed 17018654
Research compounds
Related guides
- CJC-1295 Ipamorelin Research Evidence
- CJC-1295 vs Ipamorelin
- Ipamorelin research guide
- GH peptide comparison
- Research peptides guide
- Reconstitution guide
- Storage guide
Research Use Only. Not for human or veterinary use. Not dosing or medical guidance.
